| Mrs Melinda S Barratt, DO | |
|
805 South F Street, Broken Bow, NE 68822-0647 | |
| (308) 872-6456 | |
| (308) 872-6040 |
| Full Name | Mrs Melinda S Barratt |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 805 South F Street, Broken Bow, Nebraska |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225121361 | NPI | - | NPPES |
| 200104354 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 259 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lexington Regional Health Center | Lexington, NE | Hospital |
| Chi Health Good Samaritan | Kearney, NE | Hospital |
| Entity Name | Madonna Rehabilitation Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417045642 PECOS PAC ID: 0446164081 Enrollment ID: O20031118000079 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Lexington Regional Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316016165 PECOS PAC ID: 2860415874 Enrollment ID: O20060105000221 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Lexington Regional Health Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1467417352 PECOS PAC ID: 2860415874 Enrollment ID: O20071129000331 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Jennie M Melham Memorial Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538232244 PECOS PAC ID: 5799766440 Enrollment ID: O20071129000446 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Teledigm Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667256 PECOS PAC ID: 6002130283 Enrollment ID: O20150116000478 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Sage Creek Integrative Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861946790 PECOS PAC ID: 8729374541 Enrollment ID: O20160902001778 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Bryan Hospital Kearney |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033875380 PECOS PAC ID: 5991195547 Enrollment ID: O20211214002678 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Cox-monett Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669687125 PECOS PAC ID: 0345236667 Enrollment ID: O20230627001725 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Cox Barton County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174166177 PECOS PAC ID: 8820329782 Enrollment ID: O20230630001174 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356068605 PECOS PAC ID: 5799787784 Enrollment ID: O20230707002034 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Melinda S Barratt, DO 304 W 39th St, Po Box 647, Kearney, NE 68845-2804 Ph: (308) 455-8255 | Mrs Melinda S Barratt, DO 805 South F Street, Broken Bow, NE 68822-0647 Ph: (308) 872-6456 |
News Archive
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Celsion Corporation announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.
Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation patients who undergo percutaneous coronary intervention, even if they have a high bleeding risk according to the HAS-BLED score.
In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."
If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.
› Verified 7 days ago
Mrs. Katrina A White, PA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 Memorial Drive, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2027 | |
Brett R Lindau, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 145 Memorial Drive, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2938 | |
Mrs. Shawn S Lawrence, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 805 South F Street, Broken Bow, NE 68822 Phone: 308-872-6456 Fax: 308-872-6040 | |
Dr. Norval Leon Books, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1245 North 11th Ave, Broken Bow, NE 68822 Phone: 308-872-6244 | |
Katie Thompson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 Memorial Dr, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2027 | |
Dr. Robert R Kahnk, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 145 Memorial Dr, Broken Bow, NE 68822 Phone: 308-872-2486 Fax: 308-872-2027 |